120Ana I. Haza, Almudena García and Paloma Morales[40] Kerr, J.F., Wyllie, A.H. & Currie, A.R. (1972). Apoptosis: a basic biologicalphenomenon with wide-ranging implications in tissue kinetics. British Journal <strong>of</strong>Cancer, 26, 239-257.[41] Holme, J.A., Gorria, M., Arlt, V.M., Ovrebø, S., Solhaug, A., Tekpli, X., Landvik,N.E., Huc, L., Fardel, O. & Lagadic-Gossmann, D. (2007). Different mechanismsinvolved in apoptosis following exposure to benzo[a]pyrene in F258 and Hepa1c1c7cells. Chemico-biological Interactions, 167, 41-55.[42] Hashimoto, T., Sano, T., Ito, W., Kanazawa, K., Danno, G.I. & Ashida, H. (2004). 3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole induces apoptosis and necrosis withactivation <strong>of</strong> different caspases in rat splenocytes. Bioscience, Biotechnology, andBiochemistry, 68, 964-967.[43] Shiotani, B. & Ashida, H. (2004). 3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole (Trp-P-1) triggers apoptosis by DNA double-strand breaks caused by inhibition <strong>of</strong>topoisomerase I. Carcinogenesis, 25, 1149-1155.[44] García, A., Morales, P., Arranz, N., Delgado, E., Rafter, J. & Haza, A.I. 2008.Induction <strong>of</strong> apoptosis and reactive oxygen species production by N-Nitrosopiperidineand N-Nitrosodibutylamine in human leukemia cells. Journal <strong>of</strong> Applied Toxicology,28, 455-465.[45] García, A., Morales, P., Arranz, N., Delgado, E., Rafter, J. & Haza, A.I. (2009). N-Nitrosopiperidine and N-Nitrosodibutylamine induce apoptosis in HepG2 cells viacaspase dependent pathway. Annals <strong>of</strong> the New York Academy <strong>of</strong> Science, (submittedfor publication).[46] Arranz, N., Morales, P., García, A., Rafter, J. & Haza, A.I. (2009). Induction <strong>of</strong>apoptosis by N-nitrosopyrrolidine and N-nitrosodimethylamine in human hepatoma andleukemia cells. Journal <strong>of</strong> Biochemical and Molecular Toxicology, (submitted forpublication).[47] D‘Agostini, F., Izzotti, A., Balansky, R.M., Bennicelli, C. & De Flora, S. (2005).Modulation <strong>of</strong> apoptosis by cancer chemopreventive agents. Mutation <strong>Research</strong>, 591,173-186.[48] Kim, J.G., Koh, S.H., Lee, Y.J., Lee, K.Y., Kim, Y., Kim, S., Lee, M.K. & Kim, S.H.(2005). Differential effects <strong>of</strong> dialllyl disulfide on neuronal cells depend on itsconcentration. Toxicology, 211, 86-96.[49] Koh, S.H., Kwon, H., Park, K.H., Ko, J.K., Kim, J.H., Hwang, M.S., Yum, Y.N., Kim,O.H., Kim, J., Kim, H.T., Do, B.R., Kim, K.S., Kim, H., Roh, H., Yu, H.J., Jung, K.H.& Kim, S.H. (2005). Protective effect <strong>of</strong> diallyl disulfide on oxidative stress-injuredneuronally differenciated PC12 cells. Molecular Brain <strong>Research</strong>, 133, 176-186.[50] Revel, A., Raanani, H., Younglai, E., Xu, J., Han, R., Savouret, J.F. & Casper, R.F.(2001). Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects spermfrom DNA damage and apoptosis caused by benzo(a)pyrene. Reproductive Toxicology,15, 479-486.[51] Revel, A., Raanani, H., Younglai, E., Xu, J., Han, R., Savouret, J.F. & Casper, R.F.(2003). Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung fromDNA damage and apoptosis caused by benzo(a)pyrene. Journal <strong>of</strong> Applied Toxicology,23, 255-261.
<strong>Vitamin</strong> C Protects from Oxidative DNA Damage… 121[52] Vallejo, F., Tomás-Barberán, F.A. & García-Viguera, C. (2002). Potential bioactivecompounds in health promotion from broccoli cultivars grown in Spain. Journal <strong>of</strong> theScience <strong>of</strong> Food and Agriculture, 82, 1293-1297.[53] Kondentsova, M., Vrzhesinkaia, O.A., Beketova, N.A., Gobulev, F.V. & Gorbunov,IuN. (2002). <strong>Vitamin</strong> composition in wild onion species. Voprosy Pitaniia, 71, 3–6.[54] Westerink, W.M. & Schoonen, W.G. (2007). Cytochrome P450 enzyme levels inHepG2 cells and cryopreserved primary human hepatocytes and their induction inHepG2 cells. Toxicology in Vitro, 21, 1581-1591.[55] Straif, K., Keil, U., Taeger, D., Holthenrich, D., Sun, Y., Bungers, M. & Weilan, S.K.(2000). Exposure to nitrosamines, carbon black, asbestos, and talc and mortality fromstomach, lung, and laryngeal cancer in cohort <strong>of</strong> rubber workers. American Journal <strong>of</strong>Epidemiology, 152, 297-306.[56] Liu, C.Y., Pan, P.C., Wu, M.T., Ho, C.K., Xu, X.,Yi, L., Smith, T.J. & Christiani, D.C.(2006). Dietary exposure to nitrites and nitrosamines is associated with childhood acuteleukemia. AACR Meeting Abstracts, 473–c.[57] Holme, J.A., Wiger, R., Hongslo, J.K., Soderlund, E., Brunborg, G. & Dybing, E.(1997). Cell death via interactions <strong>of</strong> agents with DNA. Advanced Molecular and CellBiology, 20, 145-182.[58] Nagai, F., Hiyoshi, Y., Sugimachi, K. & Tamura, H. (2002). Cytochrome P450 (CYP)expression in human myeloblastic and lymphoid cell lines. Biological &Pharmaceutical Bulletin, 25, 383-385.[59] Olive, P.L., Wlodek, D., Durand, R.E. & Banath, J.P. (1992). Factors influencing DNAmigration from individual cells subjected to gel electrophoresis. Experimental Cell<strong>Research</strong>, 198, 259-267.[60] Olive, P.L., Banath, J.P. & Durand, R.E. (1990). Heterogeneity in radiation inducedDNA damage and repair in tumor and normal cells measured using the ‗comet‘ assay.Radiation <strong>Research</strong>, 122, 86-94.[61] Koop, D.R., Laethem, C.L. & Tierney, D.J. (1989). The utility <strong>of</strong> p-nitrophenolhydroxylation in P450IIE1 analysis. Drug Metabolism Reviews, 20, 541-551.[62] Tassaneeyakul, W., Veronese, M.E., Birkett, D.J., Gonzalez, F.J. & Miners, J.O.(1993). Validation <strong>of</strong> 4-nitrophenol as an in vitro substrate probe for human liverCYP2E1 using cDNA expression and microsomal kinetic techniques. BiochemicalPharmacology, 46, 1975-1981.[63] Guengerich, F.P. & Shimada, T. (1991). Oxidation <strong>of</strong> toxic and carcinogenic chemicalsby human cytochrome P-450 enzymes. Chemical <strong>Research</strong> in Toxicology, 4, 391-407.[64] Hodgson, E. & Goldstein, J.A. (2001). Metabolism <strong>of</strong> toxicants: phase I reactions andpharmacogenetics. In E. Hodgson, & R.C. Smart (Eds.), Introduction to BiochemicalToxicology , Wiley-Interscience.[65] Le Gal, A., Dreáno, Y., Lucas, D. & Berthou, F. (2003). Diversity <strong>of</strong> selectiveenvironmenttal substrates for human cytochrome P450 2A6: alkoxyethers, nicotine,coumarin, N-nitrosodiethylamine, and Nnitrosobenzylmethylamine. Toxicology Letters,144, 77-91.[66] Burke, M.D. & Mayer, R.T. (1983). Differential effects <strong>of</strong> phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and cytochrome
- Page 7 and 8:
ContentsPrefaceChapter IChapter IIC
- Page 9 and 10:
PrefaceThe 6-carbon lactone known a
- Page 11 and 12:
Prefaceixbalance of antioxidant and
- Page 13 and 14:
Prefacexiprovided or is contradicto
- Page 15 and 16:
PrefacexiiiChapter IX - Background:
- Page 17 and 18:
Prefacexvdetoxification defence sys
- Page 19:
Prefacexviiprogressed faster than i
- Page 22 and 23:
2Kelsey H. Fisher-Wellman and Richa
- Page 24 and 25:
4Kelsey H. Fisher-Wellman and Richa
- Page 26 and 27:
6Kelsey H. Fisher-Wellman and Richa
- Page 28 and 29:
8Kelsey H. Fisher-Wellman and Richa
- Page 30 and 31:
10Kelsey H. Fisher-Wellman and Rich
- Page 32 and 33:
12Kelsey H. Fisher-Wellman and Rich
- Page 34 and 35:
14Kelsey H. Fisher-Wellman and Rich
- Page 36 and 37:
16Kelsey H. Fisher-Wellman and Rich
- Page 38 and 39:
18Kelsey H. Fisher-Wellman and Rich
- Page 40 and 41:
20Kelsey H. Fisher-Wellman and Rich
- Page 42 and 43:
22Kelsey H. Fisher-Wellman and Rich
- Page 44 and 45:
24Kelsey H. Fisher-Wellman and Rich
- Page 46 and 47:
26Kelsey H. Fisher-Wellman and Rich
- Page 48 and 49:
28Kelsey H. Fisher-Wellman and Rich
- Page 50 and 51:
30Kelsey H. Fisher-Wellman and Rich
- Page 52 and 53:
32Kelsey H. Fisher-Wellman and Rich
- Page 54 and 55:
34Kelsey H. Fisher-Wellman and Rich
- Page 56 and 57:
36Kelsey H. Fisher-Wellman and Rich
- Page 58 and 59:
38Kelsey H. Fisher-Wellman and Rich
- Page 60 and 61:
40Kelsey H. Fisher-Wellman and Rich
- Page 62 and 63:
42Kelsey H. Fisher-Wellman and Rich
- Page 65 and 66:
In: Handbook of Vitamin C Research
- Page 67 and 68:
Human Specific Vitamin C Metabolism
- Page 69 and 70:
Human Specific Vitamin C Metabolism
- Page 71 and 72:
Human Specific Vitamin C Metabolism
- Page 73 and 74:
Human Specific Vitamin C Metabolism
- Page 75 and 76:
Human Specific Vitamin C Metabolism
- Page 77 and 78:
Human Specific Vitamin C Metabolism
- Page 79 and 80:
Human Specific Vitamin C Metabolism
- Page 81 and 82:
mgmgmgHuman Specific Vitamin C Meta
- Page 83 and 84:
Human Specific Vitamin C Metabolism
- Page 85 and 86:
Human Specific Vitamin C Metabolism
- Page 87 and 88:
Human Specific Vitamin C Metabolism
- Page 89 and 90: Human Specific Vitamin C Metabolism
- Page 91 and 92: Human Specific Vitamin C Metabolism
- Page 93 and 94: Human Specific Vitamin C Metabolism
- Page 95 and 96: Human Specific Vitamin C Metabolism
- Page 97 and 98: Human Specific Vitamin C Metabolism
- Page 99 and 100: Human Specific Vitamin C Metabolism
- Page 101 and 102: Human Specific Vitamin C Metabolism
- Page 103 and 104: Human Specific Vitamin C Metabolism
- Page 105: Human Specific Vitamin C Metabolism
- Page 108 and 109: 88Ana I. Haza, Almudena García and
- Page 110 and 111: 90Figure 1.Ana I. Haza, Almudena Ga
- Page 112 and 113: 92Ana I. Haza, Almudena García and
- Page 114 and 115: 94Figure 3.Ana I. Haza, Almudena Ga
- Page 116 and 117: 96Ana I. Haza, Almudena García and
- Page 118 and 119: 98Ana I. Haza, Almudena García and
- Page 120 and 121: 100Ana I. Haza, Almudena García an
- Page 122 and 123: 102Ana I. Haza, Almudena García an
- Page 124 and 125: 104Ana I. Haza, Almudena García an
- Page 126 and 127: 106Ana I. Haza, Almudena García an
- Page 128 and 129: 108Ana I. Haza, Almudena García an
- Page 130 and 131: 110Ana I. Haza, Almudena García an
- Page 132 and 133: 112Ana I. Haza, Almudena García an
- Page 134 and 135: 114Ana I. Haza, Almudena García an
- Page 136 and 137: 116Ana I. Haza, Almudena García an
- Page 138 and 139: 118Ana I. Haza, Almudena García an
- Page 142 and 143: 122Ana I. Haza, Almudena García an
- Page 144 and 145: 124Ana I. Haza, Almudena García an
- Page 147 and 148: In: Handbook of Vitamin C Research:
- Page 149 and 150: Vitamin C: Dietary Requirements, Di
- Page 151 and 152: Oxidative DamageVitamin C: Dietary
- Page 153 and 154: Vitamin C: Dietary Requirements, Di
- Page 155 and 156: Vitamin C: Dietary Requirements, Di
- Page 157 and 158: Vitamin C: Dietary Requirements, Di
- Page 159 and 160: Vitamin C: Dietary Requirements, Di
- Page 161 and 162: Vitamin C: Dietary Requirements, Di
- Page 163 and 164: Vitamin C: Dietary Requirements, Di
- Page 165 and 166: Vitamin C: Dietary Requirements, Di
- Page 167 and 168: Vitamin C: Dietary Requirements, Di
- Page 169 and 170: Vitamin C: Dietary Requirements, Di
- Page 171 and 172: Vitamin C: Dietary Requirements, Di
- Page 173 and 174: In: Handbook of Vitamin C Research:
- Page 175 and 176: Pro-Oxidant vs. Antioxidant Effects
- Page 177 and 178: Pro-Oxidant vs. Antioxidant Effects
- Page 179 and 180: Pro-Oxidant vs. Antioxidant Effects
- Page 181 and 182: Pro-Oxidant vs. Antioxidant Effects
- Page 183 and 184: Patient. B.H. (38), atopic eczema.V
- Page 185 and 186: Pro-Oxidant vs. Antioxidant Effects
- Page 187 and 188: Pro-Oxidant vs. Antioxidant Effects
- Page 189 and 190: Pro-Oxidant vs. Antioxidant Effects
- Page 191 and 192:
Pro-Oxidant vs. Antioxidant Effects
- Page 193 and 194:
Pro-Oxidant vs. Antioxidant Effects
- Page 195 and 196:
Pro-Oxidant vs. Antioxidant Effects
- Page 197 and 198:
Pro-Oxidant vs. Antioxidant Effects
- Page 199 and 200:
Pro-Oxidant vs. Antioxidant Effects
- Page 201 and 202:
Pro-Oxidant vs. Antioxidant Effects
- Page 203:
Pro-Oxidant vs. Antioxidant Effects
- Page 206 and 207:
186Magdalena Stevanović and Dragan
- Page 208 and 209:
188Magdalena Stevanović and Dragan
- Page 210 and 211:
190Magdalena Stevanović and Dragan
- Page 212 and 213:
192Magdalena Stevanović and Dragan
- Page 214 and 215:
194Magdalena Stevanović and Dragan
- Page 216 and 217:
196Magdalena Stevanović and Dragan
- Page 218 and 219:
198Magdalena Stevanović and Dragan
- Page 220 and 221:
200Magdalena Stevanović and Dragan
- Page 222 and 223:
202Magdalena Stevanović and Dragan
- Page 224 and 225:
204Magdalena Stevanović and Dragan
- Page 226 and 227:
206Magdalena Stevanović and Dragan
- Page 228 and 229:
208Magdalena Stevanović and Dragan
- Page 230 and 231:
210Magdalena Stevanović and Dragan
- Page 233 and 234:
In: Handbook of Vitamin C Research
- Page 235 and 236:
Molecular Bases of the Cellular Han
- Page 237 and 238:
Molecular Bases of the Cellular Han
- Page 239 and 240:
Molecular Bases of the Cellular Han
- Page 241 and 242:
Molecular Bases of the Cellular Han
- Page 243 and 244:
Molecular Bases of the Cellular Han
- Page 245 and 246:
Molecular Bases of the Cellular Han
- Page 247 and 248:
Molecular Bases of the Cellular Han
- Page 249 and 250:
Molecular Bases of the Cellular Han
- Page 251 and 252:
Molecular Bases of the Cellular Han
- Page 253 and 254:
Molecular Bases of the Cellular Han
- Page 255 and 256:
Molecular Bases of the Cellular Han
- Page 257 and 258:
In: Handbook of Vitamin C Research
- Page 259 and 260:
Vitamin C: Daily Requirements, Diet
- Page 261 and 262:
Vitamin C: Daily Requirements, Diet
- Page 263 and 264:
Vitamin C: Daily Requirements, Diet
- Page 265 and 266:
Vitamin C: Daily Requirements, Diet
- Page 267 and 268:
Vitamin C: Daily Requirements, Diet
- Page 269 and 270:
Vitamin C: Daily Requirements, Diet
- Page 271 and 272:
Vitamin C: Daily Requirements, Diet
- Page 273 and 274:
Vitamin C: Daily Requirements, Diet
- Page 275 and 276:
Vitamin C: Daily Requirements, Diet
- Page 277 and 278:
Vitamin C: Daily Requirements, Diet
- Page 279:
Vitamin C: Daily Requirements, Diet
- Page 282 and 283:
262Alan M. Preston, Luis Vázquez Q
- Page 284 and 285:
264Alan M. Preston, Luis Vázquez Q
- Page 286 and 287:
266Alan M. Preston, Luis Vázquez Q
- Page 288 and 289:
Percent of Study Group Selecting Di
- Page 290 and 291:
270Alan M. Preston, Luis Vázquez Q
- Page 292 and 293:
272Alan M. Preston, Luis Vázquez Q
- Page 294 and 295:
274Alan M. Preston, Luis Vázquez Q
- Page 296 and 297:
276Alan M. Preston, Luis Vázquez Q
- Page 298 and 299:
278Alan M. Preston, Luis Vázquez Q
- Page 301 and 302:
In: Handbook of Vitamin C Research
- Page 303 and 304:
The Role of Vitamin C in Human Repr
- Page 305 and 306:
The Role of Vitamin C in Human Repr
- Page 307 and 308:
The Role of Vitamin C in Human Repr
- Page 309 and 310:
The Role of Vitamin C in Human Repr
- Page 311 and 312:
The Role of Vitamin C in Human Repr
- Page 313 and 314:
The Role of Vitamin C in Human Repr
- Page 315 and 316:
The Role of Vitamin C in Human Repr
- Page 317:
The Role of Vitamin C in Human Repr
- Page 320 and 321:
300Mustafa NazıroğluKeywords: Vit
- Page 322 and 323:
302Mustafa NazıroğluNO is synthes
- Page 324 and 325:
304Mustafa Nazıroğlu‗recycling
- Page 326 and 327:
306Mustafa Nazıroğluagents, such
- Page 328 and 329:
308Mustafa NazıroğluFuture Direct
- Page 330 and 331:
310Mustafa Nazıroğlu[21] Basu, TK
- Page 332 and 333:
312Mustafa Nazıroğlu[59] Cengiz M
- Page 334 and 335:
314Samar Al Sayegh Petkovšek and B
- Page 336 and 337:
316Samar Al Sayegh Petkovšek and B
- Page 338 and 339:
318Samar Al Sayegh Petkovšek and B
- Page 340 and 341:
(mgg -1 )320Samar Al Sayegh Petkov
- Page 342 and 343:
322Samar Al Sayegh Petkovšek and B
- Page 344 and 345:
324Samar Al Sayegh Petkovšek and B
- Page 346 and 347:
326Samar Al Sayegh Petkovšek and B
- Page 348 and 349:
328Samar Al Sayegh Petkovšek and B
- Page 350 and 351:
330Antonio J. López-Farré, José
- Page 352 and 353:
332Antonio J. López-Farré, José
- Page 354 and 355:
334Antonio J. López-Farré, José
- Page 356 and 357:
336Antonio J. López-Farré, José
- Page 358 and 359:
338Antonio J. López-Farré, José
- Page 360 and 361:
340Antonio J. López-Farré, José
- Page 363 and 364:
In: Handbook of Vitamin C Research
- Page 365 and 366:
Vitamin C in the Treatment of Endot
- Page 367 and 368:
Vitamin C in the Treatment of Endot
- Page 369 and 370:
Vitamin C in the Treatment of Endot
- Page 371 and 372:
Vitamin C in the Treatment of Endot
- Page 373 and 374:
Vitamin C in the Treatment of Endot
- Page 375 and 376:
In: Handbook of Vitamin C Research
- Page 377 and 378:
Vitamin C Intake by Japanese Patien
- Page 379 and 380:
Vitamin C Intake by Japanese Patien
- Page 381 and 382:
Vitamin C Intake by Japanese Patien
- Page 383 and 384:
Vitamin C Intake by Japanese Patien
- Page 385 and 386:
Vitamin C Intake by Japanese Patien
- Page 387 and 388:
In: Handbook of Vitamin C Research
- Page 389 and 390:
Reciprocal Effects of Ascorbate on
- Page 391 and 392:
Reciprocal Effects of Ascorbate on
- Page 393 and 394:
Reciprocal Effects of Ascorbate on
- Page 395:
Reciprocal Effects of Ascorbate on
- Page 398 and 399:
378Akihito Ishigamicontrols (12,13)
- Page 400 and 401:
380Akihito IshigamiFigure 3. Vitami
- Page 402 and 403:
382Akihito IshigamiFuture of the SM
- Page 405 and 406:
In: Handbook of Vitamin C Research
- Page 407 and 408:
The Importance of Food Processing o
- Page 409 and 410:
IndexAA , 249abdominal cramps, 243a
- Page 411 and 412:
Index 391atherosclerotic plaque, 23
- Page 413 and 414:
Index 393catalase, 6, 13, 169, 181,
- Page 415 and 416:
Index 395cyclooxygenase-2, 337, 341
- Page 417 and 418:
Index 397endometrium, 286, 294endon
- Page 419 and 420:
Index 399GCS, 18gel, x, 87, 92, 121
- Page 421 and 422:
Index 401hyperglycaemia, 223hypergl
- Page 423 and 424:
Index 403kinetics, 71, 120, 124, 14
- Page 425 and 426:
Index 405metastases, 182metastasis,
- Page 427 and 428:
Index 407nitrate, 14, 88, 179, 234,
- Page 429 and 430:
Index 409phosphodiesterase, 344, 35
- Page 431 and 432:
Index 411recovery, vii, 1, 5, 7, 8,
- Page 433 and 434:
Index 413steady state, 63, 76, 78st
- Page 435:
Index 415UV, 156, 191, 201, 204, 22